SCHEMBL4636877

SCHEMBL4636877

CCOC(=O)Cc1c(C)c(Sc2ccc(S(=O)(=O)NC3CC3)cc2)c2cc(C#N)ccn12

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
P4HB P07237 1/20 0.39
LMNA P02545 5/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 1/20 0.37
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
NR1H2 P55055 2/20 0.36
KDM4E B2RXH2 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
GAA P10253 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4668504 0.90 P4HB (0.40) POLBP4HBLMNAL3MBTL1ALDH1A1
SCHEMBL4636937 0.89 L3MBTL1 (0.38) POLBLMNAL3MBTL1MAPTALDH1A1
SCHEMBL4635633 0.87 L3MBTL1 (0.40) LMNAL3MBTL1MAPTALDH1A1SMN1; SMN2
SCHEMBL4635997 0.87 L3MBTL1 (0.40) LMNAL3MBTL1MAPTALDH1A1SMN1; SMN2
SCHEMBL4636272 0.83 L3MBTL1 (0.38) LMNAL3MBTL1MAPTALDH1A1SMN1; SMN2
SCHEMBL4636280 0.82 ALDH1A1 (0.45) POLBLMNAL3MBTL1MAPTALDH1A1
SCHEMBL4636980 0.79 TDP1 (0.38) POLBLMNAL3MBTL1SMN1; SMN2
SCHEMBL4635990 0.78 L3MBTL1 (0.35) POLBLMNAL3MBTL1MAPTSMN1; SMN2
SCHEMBL3327098 0.78 L3MBTL1 (0.35) POLBLMNAL3MBTL1MAPTSMN1; SMN2
SCHEMBL4636889 0.77 MEN1 (0.35) POLBLMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
EP-1931663-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2008-06-18 EP disclosed
WO-2007031747-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 POLB 4665/4885P4HB 2235/4885LMNA 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.